

A large, abstract graphic on the right side of the slide. It consists of several overlapping, curved, and faceted shapes in various shades of blue and purple, creating a sense of depth and movement. The shapes appear to be part of a larger, complex structure that is partially visible.

Breakthroughs that change patients' lives

Deb Mangone

*Vice President
Pfizer Healthcare Ireland Country Manager*

INVESTING IN IRELAND SINCE 1969



Pfizer

was one of the first pharmaceutical firms to locate in Ireland and has operated here since

1969

OVER \$9bn
invested in IRISH OPERATIONS
SINCE 1969

The medicines manufactured in Ireland are distributed to approximately **100 countries**



5,000 employees



Pfizer employees work in roles across

- Manufacturing
- Research & Development
- Commercial operations
- Global Business Services and Finance



Ireland is a manufacturing base for Pfizer globally. Many of Pfizer's leading medicines are manufactured from Irish sites.



Part of Pfizer's Worldwide Research and Development (WRD) is based in Ireland.

Our purpose

Breakthroughs that change patients' lives



Responding to the COVID-19 pandemic

Pfizer's Lightspeed Response

Project Lightspeed: circa 10-month path to develop an effective and well-tolerated vaccine following highly scientific and ethical standards





Equity

As of December 11, 2022, more than 4,3 billion Pfizer-BioNTech COVID-19 vaccines were shipped to 181 countries in every region of the world.



Moving at the
**Speed of
Science**



Pfizer Pipeline Snapshot



**Pfizer Pipeline
Snapshot as of
November 1, 2022**

Pipeline represents progress of R&D programs as of November 1, 2022

- 17 programs advanced or are new
- 4 programs discontinued since last update
- Included are 73 NMEs, 39 additional indications

Recent Approvals

- Myfembree Combination with estradiol and norethindrone acetate for Endometriosis (U.S.)

The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) of a 30-µg booster dose of the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original [15 µg] and Omicron BA.4/BA.5 [15 µg]) for individuals ages 12 years and older. The U.S. FDA also granted EUA for a 10-µg booster dose of the Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine in children 5 through 11 years of age.



**Pfizer Pipeline
Snapshot as of
July 28, 2022**

Pipeline represents progress of R&D programs as of July 28, 2022

- 12 programs advanced or are new
- 1 program discontinued since last update
- Included are 67 NMEs, 37 additional indications

Recent Approvals

- COMIRNATY® (COVID-19 Vaccine, mRNA), for COVID-19 infection in individuals 12 through 15 years of age (U.S.)

COMIRNATY® Booster (Pfizer/BioNTech COVID-19 vaccine) expanded Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) on May 17, 2022 to include a booster dose after completion of the primary series of the Pfizer-BioNTech COVID-19 Vaccine in children 5 through 11 years of age (U.S.). On June 17, 2022, FDA granted EUA of the Pfizer-BioNTech COVID-19 Vaccine as a three 3-µg dose series for children 6 months through 4 years of age (also referred to as 6 months to less than 5 years of age) (U.S.).

Rare Disorders and Unmet Needs

An estimated

400 million

people worldwide are affected by a rare disease¹

including


30 million

people in Europe²

and


300 thousand

people in Ireland³



1. International Federation of Pharmaceutical Manufacturers & Associations. www.ifpma.org/subtopics/rare-diseases/ (Accessed December 2022); 2. European Federation of Pharmaceutical Industries and Associations. www.efpia.eu/about-medicines/development-of-medicines/intellectual-property/help-us-make-rare-disease-even-rarer/ (Accessed December 2022); 3. HSE estimates

There are ~7,000 known rare diseases³



Ref 3. Ref 3.NORD New Report 2021 <https://rarediseases.org/new-report-finds-medical-treatments-for-rare-diseases-account-for-only-11-of-us-drug-spending-nearly-80-of-orphan-products-treat-rare-diseases-exclusively/> (Accessed December 2022)



So, are we ready?

The universal call to action is for
multi-stakeholder collaboration
with a united sense of urgency
so we can address the unmet needs
of people living with rare diseases in Ireland

The time is now.